Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study(SELINE)
°áÇÙ¹×È£Èí±âÁúȯ 2012³â 73±Ç 6È£ p.303 ~ p.311
ÀÌ°üÈ£(Lee Kwan-Ho) - Yeungnam University Medical Center Department of Internal Medicine
À̰迵(Lee Kye-Young) - Konkuk University Medical Center Department of Internal Medicine
Àü¿µÁØ(Jeon Young-June) - Keimyung University Dongsan Medical Center Department of Internal Medicine
Á¤¸¸È«(Jung Maan-Hong) - Kosin University College of Medicine Department of Internal Medicine
¼ÕÃáÈñ(Son Choon-Hee) - Dong-A University Medical Center Department of Internal Medicine
À̹αâ(Lee Min-Ki) - Pusan National University Hospital Department of Internal Medicine
·ùÁ¤¼±(Ryu Jeong-Seon) - Inha University Hospital Department of Internal Medicine
¾ç¼¼ÈÆ(Yang Sei-Hoon) - Wonkwang University Hospital Department of Internal Medicine
ÀÌÀçö(Lee Jae-Cheol) - University of Ulsan College of Medicine Department of Internal Medicine
±è¿µÃ¶(Kim Young-Chul) - Chonnam National University Medical School Department of Internal Medicine
±è¼±¿µ(Kim Sun-Young) - Chungnam National University Hospital Department of Internal Medicine
Abstract
Background: This study was designed to analyze the efficacy of gefitinib as a second-line therapy, according to
the clinical characteristics in Korean patients with non-small-cell lung cancer (NSCLC).
Methods: In this Phase IV observational study, we recruited patients, previously failed first-line chemotherapy, who had locally advanced or metastatic NSCLC, and who were found to be either epidermal growth factor receptor (EGFR) mutation-positive or satisfied 2 or more of the 3 characteristics: adenocarcinoma, female, and non-smoker. These patients were administered with gefitinib 250 mg/day, orally. The primary endpoints were to evaluate the objective response rate (ORR) and to determine the relationship of ORRs, depending on each patient¡¯s characteristics of modified intent-to-treat population.
Results: A total of 138 patients participated in this study. One subject achieved complete response, and 42 subjects achieved partial response (ORR, 31.2%). The subgroup analysis demonstrated that the ORR was significantly higher in patients with EGFR mutation-positive, compared to that of EGFR mutation-negative (45.8% vs. 14.0%, p=0.0004). In a secondary efficacy variable, the median progression-free survival (PFS) was 5.7 months (95% confidence interval, 3.9¡8.4 months) and the 6-month PFS and overall survival were 49.6% and 87.9%, respectively. The most common reported adverse events were rash (34.4%), diarrhea (26.6%), pruritus (17.5%), and cough (15.6%).
Conclusion: Gefitinib was observed in anti-tumor activity with favorable tolerability profile as a second-line therapy in these selected patients. When looking at EGFR mutation status, EGFR mutation-positive showed strong association with gefitinib by greater response and prolonged PFS, compared with that of EGFR mutation-negative.
Å°¿öµå
Gefitinib, Receptor, Epidermal Growth Factor, Mutation, Carcinoma, Non-Small-Cell Lung, Disease-Free Survival
KMID :
0383820120730060303
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Gefitinib was observed in anti-tumor activity with favorable tolerability profile as a second-line therapy in these selected patients. When looking at EGFR mutation status, EGFR mutation-positive showed strong association with gefitinib by greater response and prolonged PFS, compared with that of EGFR mutation-negative. The most common reported adverse events were rash (34.4%), diarrhea (26.6%), pruritus (17.5%), and cough (15.6%).